NCT02039336 2025-07-08
M13DAP
The Netherlands Cancer Institute
Phase 1/2 Completed
Clinical Trials
5 trialsNCT05054374 2025-05-23
A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT02022982 2024-03-19
PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors
Dana-Farber Cancer Institute
Phase 1 Completed
NCT02510001 2021-07-13
MErCuRIC1
University of Oxford
Phase 1 Completed
NCT02096471 2019-01-10
MEK Inhibitor
University of Alabama at Birmingham
Phase 2 Completed